Bhopal All-India Institute of Medical Sciences (AIIMS) Bhopal hopes for a nationwide clinical trial of a drug. After the completion of the first phase trial of immunosuppressive drug (Mycobacterium W), the second round of clinical trials has been started. This will include such corona patients who are normal after being infected. They have no symptoms or minor symptoms. This trial will be done on 200 patients. Prior to the trial, patients will be consulted under clinical trial regulations. After this, the third phase trial will begin. This would include those who are at greater risk for corona. Most of them will be health workers. The purpose of the trial on these is to see if they get an infection after taking the medicine.
The first phase of this drug trial at AIIMS started from May 1. In this, 40 serious corona patients were identified for trial, but only eight could be tried. Due to the serious condition of the patients and the difficult rules and conditions of the trial, 40 patients could not be tried. However, the results of the patients on which the trial was done are reported to be good. Some of these patients were on oxygen support and have recovered.
.jpg)
However, AIIMS officials say that it is too early to say how effective the drug is until the final results are reached after the completion of the trial. The trial is expected to be completed by the end of July this year. Increases immunity The drug is being trialled at AIIMS Bhopal under the supervision of the US Food and Drug Administration (FDA), Council of Scientific and Industrial Research (CSIR) and ICMR. This medicine is being given as an injection. It is an immunomodulator. It is believed that this increases the immunity of the patient, which gives him the strength to fight against diseases. Apart from AIIMS Bhopal, this medicine is also being tried in some other medical institutions including PGI Chandigarh.
AIIMS Delhi professor discovered drug for leprosy in 1960
In 1960, this medicine was discovered by a professor at AIIMS Delhi for the treatment of leprosy. However, it did not yield very effective results in the treatment of leprosy after the trial. After this, this drug was also tried for treatment of TB. There was not much success in this either.
Bhopal AIIMS director Dr. Sarman Singh said that the second phase of clinical trial has started. This includes patients who are not very sick even after being positive. The goal is to cover 200 patients. The number may also be higher. After this, the third phase will be used on health workers.
